The Desmolux product portfolio includes non-waterborne radiation curing acrylated resins and radiation curing unsaturated polyesters in acrylated diluents. The acquisition of the Desmolux product portfolio will complement Allnex’s leading position in EBECRYL UV/EB Radiation curing products and will enable Allnex to further enhance its technology leadership as it continues to address future customer needs. Moreover, with this acquisition Allnex will increase its presence in new applications, develop new markets for radcure and globalize the Desmolux business.
The deal is expected to be closed in the second half of 2013.
“We are excited about combining Bayer’s Desmolux business with Allnex’s existing radcure product portfolio,” said Frank Aranzana, CEO of Allnex. “The divestiture of the Coating Resins business of Cytec into Allnex was only completed on April 3, 2013 and we are already taking another step towards establishing the company’s new identity. This transaction will extend our portfolio of products and add new revenue streams enabling Allnex to further leverage its strong customer relationships and partner network to expand distribution worldwide.”